Enlivex Progresses to Phase II for Knee Arthritis Treatment

Enlivex (ENLV) has released an update.

Enlivex Therapeutics Ltd. has announced the successful completion of Phase I trials for Allocetra, a treatment for knee osteoarthritis, with the DSMB endorsing the move to Phase II. This next stage will be a double-blind, randomized trial to assess the safety and efficacy of the treatment compared to a placebo. The therapy is a significant development, considering the large number of individuals affected by osteoarthritis globally, with no current FDA or EMA-approved medications that can halt or reverse joint damage.

For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.